US 11932633
KRas G12C inhibitors
granted A61PA61P35/00
Quick answer
US patent 11932633 (KRas G12C inhibitors) held by Mirati Therapeutics, Inc. expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Mirati Therapeutics, Inc.
- Grant date
- Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 41
- CPC classes
- A61P, A61P35/00